VERAXA shareholders approve merger with Voyager SPAC; CHF 223,400 capital increase

Voyager Acquisition Corp./Cayman Islands

Shareholders approved absorption merger of VERAXA into Veraxa Biotech Holding AG; combined entity to rename to Veraxa Biotech AG.
Approved ordinary capital increase of CHF 223,400 for shares to be issued to Voyager shareholders.
Christoph Antz remains CEO; closing subject to Voyager shareholder vote; Nasdaq ticker expected to be VRXA.
Business combination originally announced April 22, 2025; proxy statement/prospectus filed Feb 19, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.